158 related articles for article (PubMed ID: 37792675)
1. Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer.
Chen X; Li Y; Zhou Z; Zhang Y; Chang L; Gao X; Li Q; Luo H; Westover KD; Zhu J; Wei X
Cancer Med; 2023 Oct; 12(19):19904-19920. PubMed ID: 37792675
[TBL] [Abstract][Full Text] [Related]
2. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
3. HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
[TBL] [Abstract][Full Text] [Related]
5. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
Chang Y; Park KH; Lee JE; Han KC
Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
[TBL] [Abstract][Full Text] [Related]
6. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
[TBL] [Abstract][Full Text] [Related]
7. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
8. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
9. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Sethunath V; Hu H; De Angelis C; Veeraraghavan J; Qin L; Wang N; Simon LM; Wang T; Fu X; Nardone A; Pereira R; Nanda S; Griffith OL; Tsimelzon A; Shaw C; Chamness GC; Reis-Filho JS; Weigelt B; Heiser LM; Hilsenbeck SG; Huang S; Rimawi MF; Gray JW; Osborne CK; Schiff R
Mol Cancer Res; 2019 Nov; 17(11):2318-2330. PubMed ID: 31420371
[TBL] [Abstract][Full Text] [Related]
12. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS; Browne BC; Conlon NT; O'Brien NA; Slamon DJ; Henry M; Meleady P; Clynes M; Dowling P; Crown J; O'Donovan N
Mol Cancer; 2014 Jun; 13():157. PubMed ID: 24958351
[TBL] [Abstract][Full Text] [Related]
13. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2018 Mar; 36(8):741-748. PubMed ID: 29244528
[TBL] [Abstract][Full Text] [Related]
14. A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
Franco YL; Ramakrishnan V; Vaidya TR; Mody H; Perez L; Ait-Oudhia S
J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):273-293. PubMed ID: 33389550
[TBL] [Abstract][Full Text] [Related]
15. Construction of Nucleolin-Targeted Lipid Nanobubbles and Contrast-Enhanced Ultrasound Molecular Imaging in Triple-Negative Breast Cancer.
Fang K; Wang L; Huang H; Lan M; Shen D; Dong S; Guo Y
Pharm Res; 2020 Jul; 37(7):145. PubMed ID: 32666304
[TBL] [Abstract][Full Text] [Related]
16. HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
McDermott MSJ; Conlon N; Browne BC; Szabo A; Synnott NC; O'Brien NA; Duffy MJ; Crown J; O'Donovan N
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30743996
[TBL] [Abstract][Full Text] [Related]
17. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Xu X; De Angelis C; Burke KA; Nardone A; Hu H; Qin L; Veeraraghavan J; Sethunath V; Heiser LM; Wang N; Ng CKY; Chen ES; Renwick A; Wang T; Nanda S; Shea M; Mitchell T; Rajendran M; Waters I; Zabransky DJ; Scott KL; Gutierrez C; Nagi C; Geyer FC; Chamness GC; Park BH; Shaw CA; Hilsenbeck SG; Rimawi MF; Gray JW; Weigelt B; Reis-Filho JS; Osborne CK; Schiff R
Clin Cancer Res; 2017 Sep; 23(17):5123-5134. PubMed ID: 28487443
[No Abstract] [Full Text] [Related]
18. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Ma C; Niu X; Luo J; Shao Z; Shen K
Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
[TBL] [Abstract][Full Text] [Related]
20. miR-221 confers lapatinib resistance by negatively regulating p27
Huynh TK; Huang CH; Chen JY; Yao JH; Yang YS; Wei YL; Chen HF; Chen CH; Tu CY; Hsu YM; Liu LC; Huang WC
Cancer Sci; 2021 Oct; 112(10):4234-4245. PubMed ID: 34382727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]